Furthermore, besides the observed impact in the biology of ErbB receptors, the abrogation of ST6Gal1 expression induced significant alterations in the phosphorylation levels of other cancer-associated RTKs in trastuzumab-treated cells, including the upregulation of c-Met activation, a previously established molecular carrier of α2,6NeuAc motifs [35]. Here, ST6GAL1 is linked to cancer.